NSE - Delayed Quote INR

Cipla Limited (CIPLA.NS)

1,378.90 +20.90 (+1.54%)

At close: October 30 at 3:28:21 PM GMT+5:30

Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US

PR Newswire 1mo ago

CIPLA.NS
+1.54%
500087.BO

CIPLA
Cipla Receives U.S. FDA Approval for Generic Advair Diskus®

PR Newswire 3mo ago

CIPLA.NS
+1.54%
CIPLA.BO

CIPLA-EQ
Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin® HFA

PR Newswire 6mo ago

CIPLA.NS
+1.54%
GSK.L
Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary Fibrosis

PR Newswire 6mo ago

CIPLA.NS
+1.54%
India Pharmaceutical Industry Strategic Landscape Report 2025: Competitive Analysis of Sun Pharmaceutical, Dr. Reddy's Laboratories, Cipla, Aurobindo Pharma, and Biocon

GlobeNewswire 11mo ago

CIPLA.NS
+1.54%
AUROPHARMA.NS

DRREDDY.BO
Ritedose Appoints Carolyn Berg as New Vice President of Strategic Growth

GlobeNewswire 1mo ago

CIPLA.NS
+1.54%
MRK
[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

GlobeNewswire 4mo ago

AUROPHARMA.NS

ALKEM.NS

CIPLA.NS
+1.54%
3 Indian Export Stocks That Could Benefit If The Rupee Hits 100 Against The Dollar

Simply Wall St. 16d ago

INR=X

CIPLA.NS
+1.54%
AUROPHARMA.NS
Merck's $8.4 Billion Keytruda Fortress Gets a 2028 Warning

GuruFocus.com 1mo ago

MRK

CIPLA.NS
+1.54%
Pfizer (PFE) Reaches Settlement to Extend VYNDAMAX Patent Protection Until 2031

Insider Monkey 5mo ago

PFE

HIK.L

CIPLA.NS
+1.54%
Pfizer protects $6.4bn heart disease blockbuster from generics, for now

Pharmaceutical Technology 5mo ago

PFE

HIK.L

CIPLA.NS
+1.54%
Pfizer deals extend patent life for a top-selling rare disease drug

BioPharma Dive 6mo ago

PFE

HIK.L

CIPLA.NS
+1.54%

U.S. markets closed

Cipla Limited (CIPLA.NS)

Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US

Cipla Receives U.S. FDA Approval for Generic Advair Diskus®

Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin® HFA

Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary Fibrosis

India Pharmaceutical Industry Strategic Landscape Report 2025: Competitive Analysis of Sun Pharmaceutical, Dr. Reddy's Laboratories, Cipla, Aurobindo Pharma, and Biocon

Ritedose Appoints Carolyn Berg as New Vice President of Strategic Growth

[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

3 Indian Export Stocks That Could Benefit If The Rupee Hits 100 Against The Dollar

Merck's $8.4 Billion Keytruda Fortress Gets a 2028 Warning

Pfizer (PFE) Reaches Settlement to Extend VYNDAMAX Patent Protection Until 2031

Pfizer protects $6.4bn heart disease blockbuster from generics, for now

Pfizer deals extend patent life for a top-selling rare disease drug